Kerala Ayurveda Ltd

Kerala Ayurveda Limited submitted a certificate to the BSE Limited on October 5, 2026, confirming compliance with Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018, for the quarter ended September 30, 2026. The certificate, issued by Integrated Registry Management Services Private Limited, the company's Registrar and Share Transfer Agent, confirms that securities received from depository participants for dematerialization were processed and that security certificates have been mutilated and cancelled.

Kerala Ayurveda Limited informed the Bombay Stock Exchange that the trading window for its designated persons and their immediate relatives will be closed from Wednesday, September 30, 2026, until 48 hours after the announcement of the company’s unaudited financial results for the quarter ending September 30, 2026, in compliance with the Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015; the company will separately announce the date of the Board of Directors meeting to approve the results.

Kerala Ayurveda Limited said its board approved a preferential issue of up to 720,000 equity shares with a face value of Rs 10 each at a price of Rs 190.37 per share, totaling Rs 137.07 crore, to Katra Holding Private Limited, a promoter group entity, to partially adjust an existing unsecured loan of Rs 26.41 crore. The company will convene its 34th Annual General Meeting on September 28, 2026, through video conferencing or other audio visual means, and will seek shareholder approval for the preferential issue.

Kerala Ayurveda Limited will hold a board meeting on September 4, 2026, to consider and evaluate a proposal for a preferential issue of equity shares in one or more tranches, and to convene the 34th Annual General Meeting on September 28, 2026, at 11:00 a.m. (IST) through video conferencing or other audio-visual means.

Kerala Ayurveda Ltd share price softened by 0.99% to Rs 155.8 after the company's net profit saw a mild growth of 9.19% to Rs 8.08 crore, while revenue from operations eased by 4.46% to Rs 33.19 crore in Q2FY26 over Q1FY26. The market capitalization of Pharmaceuticals industry group stocks on BSE stood at Rs 25.12 lakh crore, gaining 4.41%. It has improved by 1.16% over last one week and rose by 11.70% in last one month while the market capitalization of Kerala Ayurveda Ltd has slipped by 0.61% and 26.27% in the same period respectively. Profit before tax (PBT) of Kerala Ayurveda Ltd stood at Rs 8.23 crore in Q2 FY26, nosediving by 392.88% year-on-year, and easing 3.13% quarter-on-quarter. EBITDA came in at Rs 4 crore, crashing by 70.06% YoY and plunging by 54.61% sequentially. Total expenses contracted by 10.66% to Rs 38.89 crore in Q2FY26 over Q2FY25. During the quarter, cost of materials consumed stood at Rs 7.35 crore, posting a minor increase of 0.27% YoY, while employee benefits expense was at Rs 18.84 crore, registering a marginal contraction of 3.58% YoY. For the TTM ended FY26, revenue from operations improved 16.66% to Rs 120.33 crore, while net profit surged by 2392.86% to Rs 13.96 crore, compared to previous TTM. EBITDA jumped by 1007% to Rs 6.81 crore, and PBT tanked by 1954.55% to Rs 12.24 crore compared to previous TTM. The company's consolidated net cash flow from operating activities stood at Rs 4.83 crore in FY26, as against Rs 0.96 crore in FY25. Kerala Ayurveda Ltd tumbled by 68.99% in last one year, underperforming the benchmark BSE Sensex which has softened by 3.04% during the same period.

Kerala Ayurveda Limited will hold a board meeting on Wednesday, August 12, 2026, to consider and approve the unaudited financial results (standalone and consolidated) for the quarter ended June 30, 2026, according to a regulatory filing with the Bombay Stock Exchange. The trading window for the company's securities was closed for designated persons from June 30, 2026, and will remain so for 48 hours after the results are released.

Net Loss of Kerala Ayurveda reported to Rs 7.76 crore in the quarter ended March 2026 as against net loss of Rs 15.54 crore during the previous quarter ended March 2025. Sales rose 10.92% to Rs 34.74 crore in the quarter ended March 2026 as against Rs 31.32 crore during the previous quarter ended March 2025. For the full year,net loss reported to Rs 16.56 crore in the year ended March 2026 as against net loss of Rs 14.70 crore during the previous year ended March 2025. Sales rose 8.99% to Rs 131.15 crore in the year ended March 2026 as against Rs 120.33 crore during the previous year ended March 2025. ParticularsQuarter EndedYear EndedMar. 2026Mar. 2025% Var.Mar. 2026Mar. 2025% Var. Sales34.7431.32 11 131.15120.33 9 OPM %-20.44-32.38 --13.53-4.15 - PBDT-6.29-11.89 47 -10.88-7.26 -50 PBT-7.98-13.81 42 -16.36-12.24 -34 NP-7.76-15.54 50 -16.56-14.70 -13 Powered by Capital Market - Live

Kerala Ayurveda will hold a meeting of the Board of Directors of the Company on 25 May 2026.

Kerala Ayurveda will hold a meeting of the Board of Directors of the Company on 25 March 2026.Powered by Capital Market - Live

Kerala Ayurveda announced that an Extra Ordinary General Meeting (EGM) of the Company will be held on 14 March 2026.Powered by Capital Market - Live